logo-loader
viewAvacta Group PLC

Director/PDMR Shareholding

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:10.0pt;font-family:"Times","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bc{size:595.0pt 842.0pt;margin:69.25pt 98.85pt 49.65pt 70.9pt;}div.bc{}p.dz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:115%}span.dx{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.ea{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: right}span.dv{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.eb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}p.ec{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}p.ed{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify;text-justify:inter-ideograph; line-height:115%}span.dr{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black;background:#FEFEFE} p.ee{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:115%}span.dp{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:black; background:#FEFEFE}p.ef{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 11.0pt; text-align: center}span.dn{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.eg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold}span.dl{font-size:10.0pt;font-family: "Arial","sans-serif"}table.eh{width:454.5pt;margin-left:-10.8pt;border-collapse:collapse}td.dh{width:26.35pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ei{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 11.0pt; margin-left: 18.0pt; margin-right: 0cm; margin-top: 5.0pt; text-indent: -18.0pt}span.dj{font-size:10.0pt;font-family:"Arial","sans-serif"} td.de{width:393.8pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.ej{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 11.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt}span.dg{font-size:10.0pt; font-family:"Arial","sans-serif"}td.dc{width:26.35pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.ek{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:5.0pt;margin-right:0cm;margin-bottom: 11.0pt;margin-left:0cm}td.db{width:120.15pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.da{width:250.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cz{width:393.8pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.el{width:250.5pt;border-collapse:collapse}tr.cx{height:4.2pt} td.cy{padding:0cm 5.4pt 0cm 5.4pt;height:4.2pt}p.em{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt}span.cu{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}td.ct{width:120.15pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cq{width:250.8pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.en{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:11.0pt}td.cr{width:136.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.2pt}table.eo{width:249.75pt;border-collapse:collapse}td.cp{width:108.8pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.co{width:108.85pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt} td.cn{width:108.8pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.cm{width:108.85pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ep{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:5.0pt;margin-right:0cm;margin-bottom: 11.0pt;margin-left:18.0pt;text-indent:-18.0pt}p.eq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: justify; text-justify: inter-ideograph}span.ci{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:red}span.cg{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:red}p.er{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 205.55pt; margin-right: 9.2pt; margin-top: 0cm}p.k,li.k,div.k{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";}p.es{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%}table.et{margin-left:auto;margin-right:auto;width:440.9pt;border-collapse:collapse} td.ca{width:230.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.eu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}span.cd{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}p.ev{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm}td.by{width:188.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.ew{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:115%}span.bz{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}span.bx{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}span.bw{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif"}p.ex{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-justify: inter-ideograph;line-height:115%} span.bv{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"}p.ey{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; text-align: justify; text-decoration: underline; text-justify: inter-ideograph}span.ez{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; line-height: 115%; text-decoration: none}p.fa{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: right}p.fb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}span.br{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.fc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph}span.bo{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:black}p.fd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: justify; text-decoration: underline; text-justify: inter-ideograph}span.bm{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:windowtext} span.bl{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:windowtext}p.fe{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-right: 9.2pt}p.ff{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:11.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify;text-justify:inter-ideograph; line-height:115%}a.bh{font-weight: bold}span.bf{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black}span.be{color: blue; text-decoration: underline}p.fg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-right: -7.1pt} /**/
RNS Number : 3469U
Avacta Group PLC
22 November 2019
 

 

22 November 2019

Avacta Group plc

("Avacta", the "Company" or the "Group")

 

Director/PDMR Shareholdings

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces the following Directors' dealings undertaken for tax planning purposes:

 

Dr Trevor Nicholls, Non Executive Director, sold 108,333 ordinary shares of 10p each ("Ordinary Shares")  at a price of 17.50 pence per Ordinary Share and his ISA purchased 107,455 Ordinary Shares at a price of 17.63 pence per Ordinary Share.

 

Following the transactions, the total beneficial interest of Dr Nicholls is 107,455 Ordinary Shares, representing less than 0.1% of the total voting rights.

 

Details of the full notifications received by the Company are set out below:

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.  

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Nicholls

2.           

Reason for the Notification

a)

Position/status

Non-executive Director

b)

Initial notification/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares of 10p each

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

17.5 pence (sell)

17.63 pence (buy)

108,333

107,455

d)

Aggregated information:

Aggregated volume

Price

 

As above

e)

Date of the transaction

21 November 2019

f)

Place of the transaction

London Stock Exchange

 

 

 

- Ends -

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Giles Rolls - Corporate Finance

Tim Redfern - ECM

 

WG Partners (Joint Broker)

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments (TPI)

Zoe Alexander / Andy Thacker

 

Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Harriet Jackson

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0) 203 657 0050

www.turnerpope.com

 

 

Tel: +44 (0)7764 947 137

Tel: +44 (0)7544 275 882

[email protected]

 

Tel: +44 (0)7787 502 947

[email protected] 

 

 

About Avacta Group plc - https://www.avacta.com

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

 

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn.  Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost. 

 

Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

 

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in the middle of 2020.

 

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, and a partnership with ADC Therapeutics. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

 

Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHCKBDNFBDKCDB

Quick facts: Avacta Group PLC

Price: 16.25

Market: AIM
Market Cap: £28.59 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

on 23/10/19

RNS

Holding(s) in Company

1 week, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

4 weeks ago

Holding(s) in Company

4 weeks ago

Holding(s) in Company

4 weeks, 1 day ago

Holding(s) in Company

4 weeks, 1 day ago

Holding(s) in Company

1 month ago